ERBB2 and cancer: A docking study against overexpressed receptors (HER-2, and Folate receptors) in cancer cells, investigated the molecular level drug performance of the DOX-CM-ABRS-SPIONs, which revealed promising results as compared to the standard, free-DOX solution [116].